Drugs effects on ventricular repolarization

A critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices

Alan S. Bass, Gordon F. Tomaselli, Roy Bullingham, Lewis B. Kinter

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

A growing number of drugs and drug combinations inhibit cardiac potassium ion conductance and ventricular repolarization, and increase cardiac APD, QT interval, and risk of potentially fatal TdP. The past decade has seen an explosion of research advances into the mechanism of action underpinning these observations, and an unprecedented level of collaboration between academia, industry, and regulatory authorities to define effective strategies for accurate prediction of increased TdP risk (if any) in humans, based upon nonclinical and/or clinical endpoints. Because the incidence of TdP is so very low, even for drugs for which the association is known, the risk can only be assessed based upon surrogate markers (signals) in in vitro and in vivo non-clinical studies as well as in clinical trials. In this article, we review both the strengths and weaknesses of current methodologies and regulatory practices for assessment of TdP risk for pharmaceuticals.

Original languageEnglish (US)
Pages (from-to)12-21
Number of pages10
JournalJournal of Pharmacological and Toxicological Methods
Volume52
Issue number1
DOIs
StatePublished - Jul 1 2005
Externally publishedYes

Fingerprint

pamidronate
Pharmaceutical Preparations
Explosions
Drug Combinations
Potassium
Industry
Biomarkers
Clinical Trials
Ions
Incidence
Research
In Vitro Techniques

Keywords

  • Potassium ion conductance
  • TdP
  • Ventricular repolarization

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Drugs effects on ventricular repolarization : A critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices. / Bass, Alan S.; Tomaselli, Gordon F.; Bullingham, Roy; Kinter, Lewis B.

In: Journal of Pharmacological and Toxicological Methods, Vol. 52, No. 1, 01.07.2005, p. 12-21.

Research output: Contribution to journalReview article

@article{b3986add458d4a2bb468d661a722f5c2,
title = "Drugs effects on ventricular repolarization: A critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices",
abstract = "A growing number of drugs and drug combinations inhibit cardiac potassium ion conductance and ventricular repolarization, and increase cardiac APD, QT interval, and risk of potentially fatal TdP. The past decade has seen an explosion of research advances into the mechanism of action underpinning these observations, and an unprecedented level of collaboration between academia, industry, and regulatory authorities to define effective strategies for accurate prediction of increased TdP risk (if any) in humans, based upon nonclinical and/or clinical endpoints. Because the incidence of TdP is so very low, even for drugs for which the association is known, the risk can only be assessed based upon surrogate markers (signals) in in vitro and in vivo non-clinical studies as well as in clinical trials. In this article, we review both the strengths and weaknesses of current methodologies and regulatory practices for assessment of TdP risk for pharmaceuticals.",
keywords = "Potassium ion conductance, TdP, Ventricular repolarization",
author = "Bass, {Alan S.} and Tomaselli, {Gordon F.} and Roy Bullingham and Kinter, {Lewis B.}",
year = "2005",
month = "7",
day = "1",
doi = "10.1016/j.vascn.2005.04.010",
language = "English (US)",
volume = "52",
pages = "12--21",
journal = "Journal of Pharmacological and Toxicological Methods",
issn = "1056-8719",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Drugs effects on ventricular repolarization

T2 - A critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices

AU - Bass, Alan S.

AU - Tomaselli, Gordon F.

AU - Bullingham, Roy

AU - Kinter, Lewis B.

PY - 2005/7/1

Y1 - 2005/7/1

N2 - A growing number of drugs and drug combinations inhibit cardiac potassium ion conductance and ventricular repolarization, and increase cardiac APD, QT interval, and risk of potentially fatal TdP. The past decade has seen an explosion of research advances into the mechanism of action underpinning these observations, and an unprecedented level of collaboration between academia, industry, and regulatory authorities to define effective strategies for accurate prediction of increased TdP risk (if any) in humans, based upon nonclinical and/or clinical endpoints. Because the incidence of TdP is so very low, even for drugs for which the association is known, the risk can only be assessed based upon surrogate markers (signals) in in vitro and in vivo non-clinical studies as well as in clinical trials. In this article, we review both the strengths and weaknesses of current methodologies and regulatory practices for assessment of TdP risk for pharmaceuticals.

AB - A growing number of drugs and drug combinations inhibit cardiac potassium ion conductance and ventricular repolarization, and increase cardiac APD, QT interval, and risk of potentially fatal TdP. The past decade has seen an explosion of research advances into the mechanism of action underpinning these observations, and an unprecedented level of collaboration between academia, industry, and regulatory authorities to define effective strategies for accurate prediction of increased TdP risk (if any) in humans, based upon nonclinical and/or clinical endpoints. Because the incidence of TdP is so very low, even for drugs for which the association is known, the risk can only be assessed based upon surrogate markers (signals) in in vitro and in vivo non-clinical studies as well as in clinical trials. In this article, we review both the strengths and weaknesses of current methodologies and regulatory practices for assessment of TdP risk for pharmaceuticals.

KW - Potassium ion conductance

KW - TdP

KW - Ventricular repolarization

UR - http://www.scopus.com/inward/record.url?scp=22444444118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22444444118&partnerID=8YFLogxK

U2 - 10.1016/j.vascn.2005.04.010

DO - 10.1016/j.vascn.2005.04.010

M3 - Review article

VL - 52

SP - 12

EP - 21

JO - Journal of Pharmacological and Toxicological Methods

JF - Journal of Pharmacological and Toxicological Methods

SN - 1056-8719

IS - 1

ER -